AbbVie Inc. (NYSE:ABBV)

AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases. AbbVie aims to help patients’ live healthier lives and collaborate on sustainable healthcare solutions.

AbbVie Inc. (NYSE:ABBV)’s Financial Overview

AbbVie Inc. (NYSE:ABBV) surged 3.58% yesterday to close its trading session at $61.59. The company has 1 year Price Target of $70. AbbVie Inc. has 52-Week high of $68.12 and 52-Week Low of $50.71. The stock touched its 52-Week High on Aug 15, 2016 and 52-Week Low on Jan 14, 2016. The stock traded with the volume of 11.85 Million shares yesterday. The firm shows the market capitalization of $100.09 Billion.

AbbVie Inc. (NYSE:ABBV) reported its last quarterly earnings on Sep 16 where the firm reported its Actual EPS of $1.21/share against the analyst consensus estimate of $1.2/share. The difference between the actual and expected EPS is $0.01 a share with a surprise factor of 0.8%.

The firm is trading with SMA20 of 2.86 Percent, SMA50 of 0.67 Percent and SMA200 of 1.85 percent. AbbVie Inc. has P/S value of 3.97 while its P/B value stands at 15.55. Similarly, the company has Return on Assets of 10.1 percent, Return on Equity of 117.5 percent and Return on Investment of 16.9 Percent. The company shows Gross Margin and Operating Margin of 77.3 percent and 36.2 percent respectively.

Many brokerage firms are involved in issuing their ratings on AbbVie Inc. (NYSE:ABBV). On 31-Oct-16 Credit Suisse Downgrade AbbVie Inc. Stock  to Neutral. Another firm also rated the stock on 18-Oct-16 where Leerink Partners Initiated the stock to Mkt Perform.

The Stock currently has Analyst’ mean Recommendation of 2.4 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.

The 21 analysts offering 12-month price forecasts for AbbVie have a median target of 70.00, with a high estimate of 90.00 and a low estimate of 49.00. The median estimate represents a +13.65% increase from the last price of 61.59.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

Novavax, Inc. (NASDAQ:NVAX)

NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women’s health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as vehicles for the delivery of a wide variety of drugs and other therapeutic products, including certain hormones, anti-bacterial and anti-viral products and vaccine adjuvants.

Novavax, Inc. (NASDAQ:NVAX)’s Financial Outlook

The 6 analysts offering 12-month price forecasts for Novavax Inc have a median target of 1.50, with a high estimate of 12.00 and a low estimate of 1.50. The median estimate represents a +18.11% increase from the last price of 1.27.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

According to Zacks Investment Research, Novavax, Inc. has a Consensus Recommendation of 2.67. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).

The Stock fell -0.78% and closed its last trading session at $1.27. The company has the market capitalization of $344.47 Million. The stock has 52-week high of $9.23 and 52-Week low of $1.16. The firm touched its 52-Week high on Dec 2, 2015 and 52-Week low on Sep 16, 2016. The company has volume of 11.79 Million shares. The company has a total of 271.24 Million shares outstanding.

Novavax, Inc. (NASDAQ:NVAX) in the last quarter reported its actual EPS of $-0.24/share where the analyst estimated EPS was $-0.26/share. The difference between the actual and Estimated EPS is $0.02. This shows a surprise factor of 7.7 percent.

The company has YTD performance of -84.86 percent. Beta for Novavax, Inc. stands at 1.82 while its ATR (average true range) is 0.1. The company has Weekly Volatility of 4.32%% and Monthly Volatility of 8.13%%.

Novavax, Inc. has distance from 20-day Simple Moving Average (SMA20) of -7.4%, Distance from 50-Day Simple Moving Average of -22 percent and Distance from 200-Day Simple Moving Average of -74.6%.

The Company currently has ROA (Return on Assets) of -61.5 percent, Return on Equity (ROE) of -189.1 Percent and Return on Investment (ROI) of -53.6% with Gross margin of 0 percent and Operating & Profit margin of 0% and 0% respectively.

 

SHARE